Latest news with #healthcareindustry
Yahoo
16-07-2025
- Business
- Yahoo
Hemostats Market worth $4.00 billion by 2030 with 6.4% CAGR
DELRAY BEACH, Fla., July 16, 2025 /PRNewswire/ -- The global Hemostats Market, valued at US$2.80 billion in 2024 stood at US$2.90 billion in 2025 and is projected to advance at a resilient CAGR of 6.4% from 2025 to 2030, culminating in a forecasted valuation of US$4.00 billion by the end of the period. The escalation in global accident rates has led to a surge in surgical procedures characterized by extended operating durations. A significant contributor to hemorrhage in surgical and trauma cases is the suboptimal application of conventional wound closure methods, including sutures, staples, and various hemostatic agents. This inadequacy underscores the growing demand for advanced blood loss management solutions, particularly effective hemostatic products, to optimize patient outcomes during surgical interventions. In this report, the hemostats market is segmented by type, formulation, application, end user, and region. Download PDF Brochure: Browse in-depth TOC on "Hemostats Market" 186 - Tables43 - Figures215 - Pages By type, the hemostats market is segmented into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats based on type. The oxidized regenerated cellulose-based hemostats segment accounted for the largest share of the hemostats market in 2024. ORC-based hemostatic agents have emerged as the preferred choice for surgical hemostasis due to their proven efficacy across a range of surgical specialties, including orthopedics, cardiovascular, and general surgery. These hemostats consistently demonstrate reliable hemostatic performance, making them indispensable in various intraoperative settings. Their versatility across diverse operating room conditions ensures that they are often the clinician's first choice for managing complex clinical scenarios. One of the substantial advantages of ORC-based hemostats is their bioabsorbable composition, which eliminates the need for surgical removal post-procedure and minimizes the risk of foreign-body reactions. Furthermore, certain ORC formulations possess inherent antimicrobial properties, providing an added defense against surgical site infections and thereby enhancing patient safety and post-operative outcomes. The increasing incidence of trauma cases and emergency surgeries has intensified the demand for prompt and effective hemostatic interventions within healthcare systems. In light of this trend, institutions are compelled to integrate reliable hemostatic agents into standard surgical protocols, driven by the dual objectives of improving surgical outcomes and reducing intraoperative blood loss. By formulation, the global hemostats market is differentiated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2024, the matrix & gel hemostats segment dominated the hemostats market. These formulations effectively balance versatility and efficacy, making them suitable for a wide range of surgical applications. Matrix and gel hemostats are particularly advantageous due to their straightforward application, even in challenging anatomical locations. Their ability to conform to irregular wound morphologies allows them to effectively address both profuse and oozing bleeding scenarios. Many formulations are compatible with laparoscopic techniques, facilitating the advancement of minimally invasive surgery. Moreover, certain matrix and gel combinations are integrated with active agents such as thrombin, which significantly enhances hemostatic performance and expedites clot formation. By applications, the hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. The reconstructive surgery segment is expected to witness the highest CAGR during the forecast period in the hemostats market. The observed increase in surgical interventions can be attributed to the rising prevalence of aesthetic and trauma-related procedures, including skin grafting, breast reconstruction, and craniofacial surgeries. The growing recognition and acceptance of aesthetic treatments, alongside improved access to surgical options, are further driving this demand. Additionally, the rising incidence of cancer-related surgeries, particularly post-mastectomy reconstructions, as well as trauma cases, are significant contributors to market growth. These procedures often involve delicate tissues with high vascularity, where meticulous hemostatic control is essential. This underscores the critical need for effective hemostatic agents in the operating room. Furthermore, advancements in reconstructive technologies are accelerating the adoption of specialized hemostatic products, enhancing outcomes in this evolving sector. By end user, the hemostats market can be divided by end user into three main categories: Hospitals, specialty clinics, and other end users. Hospitals represent the most substantial segment of the hemostats market, primarily due to the high volume of surgical procedures performed within their facilities. The intricate nature of these surgeries, along with the presence of specialized surgical departments, contributes significantly to the growing demand for effective bleeding control solutions. Complex and emergency cases, which frequently arise in hospitals, necessitate a reliable means of managing blood loss, thereby creating a continuous need for advanced hemostatic products. Additionally, hospitals often serve as the pioneers in adopting new surgical technologies and innovative products. This proactive approach is made possible by their enhanced funding capabilities and well-developed procurement processes, allowing them to stay at the forefront of medical advancements. The presence of highly skilled surgical specialists and comprehensive post-operative care units further amplifies the need for efficient hemostatic agents. These factors collectively ensure that hospitals remain a critical driver of demand in the hemostats market as they seek to improve patient outcomes and enhance surgical efficacy through cutting-edge bleeding control solutions. By geography, the market for hemostats has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the predominant portion of the hemostats market. North America is at the forefront of the hemostats market, propelled by its advanced healthcare infrastructure and the swift integration of cutting-edge medical technologies. This region exhibits a robust demand for both cosmetic and restorative procedures, significantly influenced by the escalating geriatric demographic and an uptick in surgical interventions. The increasing incidence of chronic diseases is projected to further amplify the volume of surgical procedures, thereby enhancing the requirement for effective hemostatic agents. The region's leadership in both innovation and market share is underscored by the concentration of numerous key players in the hemostats industry. Additionally, the high levels of disposable income and elevated standard of living in nations such as the US and Canada significantly contribute to the growing demand for premium medical treatments. Request Sample Pages : The prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey). Among other developments, these companies adopted strategies such as partnerships, collaborations, agreements, integrations, acquisitions, product launches, and expansions to strengthen their presence in the hemostats market. Johnson & Johnson Services, Inc. (US): In 2024, Johnson & Johnson Services, Inc. maintained its dominant position in the hemostats market, attributed to its expansive distribution networks across North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The company's extensive portfolio is particularly notable within the oxidized regenerated cellulose-based hemostats segment, with SURGICEL as its flagship brand for hemostatic agents. To bolster its market leadership, Johnson & Johnson leverages a strategic framework encompassing expansions, regulatory approvals, and innovative product launches. A significant move was made in May 2022, when Ethicon, a subsidiary under the Johnson & Johnson Medtech umbrella, acquired GATT Technologies B.V. This acquisition aims to enhance its biosurgery portfolio by incorporating synthetic polymer-based hemostatic technologies, exemplified by the development of advanced solutions such as the ETHIZIA Hemostatic Patch. Such strategic initiatives are pivotal in amplifying their market share and reinforcing Johnson & Johnson's entrenched position within the hemostats sector. Baxter (US) Baxter has emerged as a dominant force in the hemostats market as of 2024, securing a substantial market share largely due to its extensive and effective sales and distribution networks. With operations spanning over 100 countries, Baxter leverages both direct and indirect sales channels to optimize product reach and accessibility. The company's commitment to research and development is exemplary, facilitating the introduction of cutting-edge products that address evolving clinical needs. In addition to its organic growth strategies, such as new product launches, Baxter is also pursuing inorganic growth through strategic acquisitions, further solidifying its competitive position in the hemostats sector. Pfizer, Inc. (US) Pfizer, Inc. is a leading entity in the hemostats market as of 2024, operating within a robust global framework that spans approximately 125 countries, including regions such as North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company's established operations in the US provide a strategic platform for further penetration into emerging markets, thereby augmenting its geographical footprint. The rising adoption of foam-based hemostats is a key driver of significant revenue generation for Pfizer's hemostatic product offerings, reflecting a shift towards innovative solutions in the surgical and trauma care sectors. For more information, Inquire Now! Related Reports: Biosurgery Market Collagen & Gelatin Market Orthopedic Devices Market Biomaterials Market Adhesion Barrier Market Get access to the latest updates on Hemostats Companies and Hemostats Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
30-06-2025
- Business
- Forbes
Medical Manufacturers And Tariffs: Where Things Stand Today
Tariffs are rapidly shaping the way life-saving medical products are made and moved around the ... More world. We often discuss tariff impact in terms of steel and aluminum, semiconductors and electronics. But they're also rapidly shaping the way life-saving products are made and moved around the world. Medical manufacturing is a global game—from pharmaceutical ingredients to pacemakers to the gloves and gowns worn in operating rooms. For manufacturers in the space, that's no revelation—the pandemic taught us just how vulnerable the healthcare industry is to a fractured global supply chain. That means it's also sensitive to shifting trade policy. It's not as easy as declaring that tariffs are 'good' or 'bad' for medical manufacturers, as is the case in most industries. The impact is complex. Let's explore how different corners of the industry—pharma, devices, and personal protective equipment—have been impacted by tariffs so far, what could be coming down the line, and how companies are reacting. The Tariff Impact On Pharmaceuticals In January, President Trump announced plans to bring a 25% tariff to pharmaceuticals, a move that would end a decades-long tariff exemption for the drug industry. But months later, and after the White House's investigations into the national security implications of such a measure concluded, still no tariffs have come to fruition. As they await further developments, drugmakers have responded in a variety of ways. Several major companies have announced plans to bring some operations back to the U.S., 'including Eli Lilly, Roche, and Novartis, [who] Others have been hustling to stock their shelves with the ingredients they need before prices go back up. Imports surged earlier this year, with March seeing a year-over-year increase of 160% to $50.2 billion. However, the trend cooled significantly in April, as pharma imports dropped back down to $24.2 billion. Experts told Axios the decrease could be due to an inventory bubble created with the earlier import rush, which is 'putting pressure on the companies to sell their products before they expire.' The Tariff Impact On Medical Devices While drugmakers remain exempt from tariffs for the time being, the same can't be said for medical devices. The industry enjoyed a carve out from tariffs during the first Trump administration—not so in 2025. Several prominent industry players are pushing for a reprieve they say is necessary to maintain status quo when it comes to supplies for hospitals. The American Health Association has said tariffs 'could have significant implications for healthcare,' and that an AHA data analysis 'found that the United States had imported over $75 billion in medical devices and supplies in 2024. Among the imports were syringes, blood pressure cuffs, IV saline bags, and surgical tools,' AAMC reported. Most medical device manufacturers source from across the globe for the various parts they need. While the current 90-day tariff delay struck with China has pushed off financial implications for now, companies are sizing up a likely significant impact on the bottom line should higher tariffs return. Johnson & Johnson's MedTech division, which produces orthopedic and cardiac implants, expects to face a $400 million headwind due to duties on Chinese imports, the company has said. The company's CEO, Joaquin Daoto, says that it's tax policy, rather than tariffs, that would be 'the most effective' way to bring medical manufacturing back to the U.S. The Tariff Impact On Personal Protective Equipment The impact on PPE has been more immediate and visible. The industry has been subject to a variety of tariffs since May 2024, when the Biden administration announced a Chinese import tax on goods like surgical masks, medical gloves, and isolation gowns. The tariffs generally range from 7.5% to 25%, depending on the item. Syringes and needles are subject to a 100% levy. These measures aim to build a more resilient healthcare ecosystem in the wake of the pandemic. But about half of all PPE still comes from China, analysts have said, so American PPE manufacturers have welcomed with open arms the additional tariffs on Chinese goods. 'In our case, successive administrations — both Republic and Democratic — have recognized that these products are not competing on a level playing field,' American Medical Manufacturers Association CEO Eric Axel, whose organization represents PPE makers, told NBC News. The Future For Medical Manufacturers Tariffs are reshaping medical manufacturing, but the effects vary widely across sectors. Pharma companies are in a holding pattern, unsure whether longstanding exemptions will hold under the Trump administration. Device makers face mounting cost pressures, while PPE suppliers have enjoyed additional help against Chinese companies who have a leg up when it comes to production cost. All three sectors know that as the Trump administration considers further policy, and as the administration's trade talks with China progress, things could change in a hurry. What's clear in the meantime is that no company can afford to stand still. Tariffs are adding complexity to a challenging supply chain environment, and manufacturers must rethink their sourcing strategies, pricing models, and contingency plans. Trade policy will continue to evolve—but it's vital that we improve long-term resiliency in the world of medical manufacturing.
Yahoo
29-06-2025
- Business
- Yahoo
UBS Reaffirms Buy on Elevance Despite Adjusted 2025 Earnings Outlook
Elevance Health, Inc. (NYSE:ELV) ranks among the best fundamental stocks to buy according to hedge funds. On June 17, UBS reaffirmed its Buy rating and $555 price target for Elevance Health, Inc. (NYSE:ELV), even after the company modified its 2025 earnings distribution. Elevance Health, Inc. (NYSE:ELV) originally predicted that first-half earnings would account for 62–63% of full-year results. However, the company now expects them to account for 60%. In order of significance, Elevance Health, Inc. (NYSE:ELV) identified three factors that impacted second-quarter earnings expectations: higher underlying clarity in Affordable Care Act (ACA) populations after membership erosion, out-of-network billing difficulties in behavioral health services centered on exchanges, and Medicaid cost trends not slowing down as quickly as expected. To address these second-quarter trends, Elevance Health, Inc. (NYSE:ELV) is looking into ways to minimize expenses in order to boost performance in the second half of the year. Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Forbes
25-06-2025
- Health
- Forbes
The Amazing Ways AI Agents Will Transform Healthcare
AI agents represent the next transformational wave in healthcare, moving beyond simple diagnosis ... More tools to autonomous systems that can schedule appointments, create detailed medical reports, and monitor patients remotely without human intervention. Healthcare is already a hotbed of AI activity, which has more than proved its worth as a tool for diagnosing illness, monitoring recovery, and developing new medicines. But globally, the industry is still grappling with longstanding challenges, including shortages of clinical staff, aging populations, and managing the front-loaded costs of transitioning to more preventative models of healthcare. This is where AI agents, the next wave of AI transformation, will come in. Compared to existing AI (think of the current generation of language-based chatbots like ChatGPT), Agentic AI is capable of carrying out far more complex tasks with minimal human interaction. To give a simple example, a non-agentic computer vision-based AI algorithm can be used to scan medical images and spot early warning signs of cancer. An agentic AI, on the other hand, could cross-reference the images with other clinical patient data, create a detailed report for a doctor, and schedule a follow-up appointment, all without human involvement. This switch from passive provider of information to active action-taking is what defines the newest generation of tools and applications driven by agentic AI. Experts predict it will soon be just as transformational to healthcare as today's cutting-edge computer vision, chatbots and other AI innovations have proven to be. So here's an overview of how it may soon be put to work in hospitals, doctors' surgeries, and care homes near you. Agentic Healthcare Intelligence Several use cases for agentic applications have been identified in healthcare. Although most are currently theoretical, they give us an idea of how agents could surpass the capability of non-agentic tools and apps. Automated triage and scheduling systems could relieve clinical and administrative staff of much of the burden of routine procedures and paperwork. Rather than simply asking patients to answer questions, it can use computer vision to carry out initial examinations and flag urgent cases for immediate help. AI agents have also been built to assist with clinical decision-making. By augmenting large language models like GPT-4 with tools to understand MRI, CT and other medical data, one test found an agent could reach a correct diagnosis in 91% of cases. They will also become increasingly useful in remote patient monitoring. Their ability to make more accurate decisions about when to intervene and how to protect patient privacy and security will mean more people can stay out of hospital and be treated at home. Agents are even being put to use in clinical trials, carrying out tasks such as screening applications, matching candidates to trials and booking transportation to the test facility. For non-clinical use, the AI health monitors we use on smartwatches and fitness bands will become much smarter and more proactive. Rather than simply measuring heart rate, skin temperature and so on, they'll be ready to give us a holistic overview of our health at any time and then monitor the action we take towards improving it. Finally, agents will help complete administrative tasks more efficiently by automating decisions around scheduling, reading and replying to emails, and handling billing and commissioning. While this can be done by existing AI on a task-by-task basis, agents will take oversight of entire workflows or even business functions, reducing human error and time spent on routine work. A great deal of academic research is currently taking place into how we can safely use and understand the impact of agentic AI in healthcare. Answering these questions will play a bit part in helping these use cases get off the ground. What About The Risks? With greater autonomy and the ability to interact with external systems, AI agents clearly introduce new risks that could be particularly dangerous in healthcare ecosystems. Data security is an obvious one, and new security measures will be required to balance the need for agents to access personal data with the dangers this creates. Confidential patient information, as well as control over critical systems, could be at stake if agents are compromised by malicious individuals or groups or just don't work like they're supposed to. Agents will also force healthcare service providers to answer questions and provide assurances about accountability. AI can't take responsibility for its actions, so how is it shared between the healthcare industry, AI developers, and the clinical staff and patients who use it? Then there's the simple fact that AI is often wrong. Whether it's down to bad data or hallucination, it simply isn't right 100 percent of the time. Of course, neither are humans. So when is it right to hand over the reins? And, of course, we're far from the point where anyone thinks it's right to let machines make decisions that affect humans without human oversight. So, how do we make sure that oversight is in place, effective and accountable? Overcoming all of these challenges will be critical to safely integrating agentic AI into the healthcare system and unlocking the benefits it promises. The Future Of Agents In Healthcare By the end of the decade, we can expect agentic AI to have radically changed the way healthcare is delivered, managed and experienced. Globally, healthcare has for some time understood the importance of moving from reactive to preventative care. Agents will proactively interact with wearables and home sensors to enable far earlier interventions when warning signs are detected. This will happen within an agentic ecosystem, which delivers fully personalized care by fine-tuning treatment in response to patient data. Meanwhile, the workload of clinical professionals will involve far less time spent filling in forms or reviewing notes and more time using their uniquely human skills and experience to improve patient outcomes. Access to healthcare in underserved areas could increase, with agents acting as gateways to telemedicine services, triaging initial contacts as well as freeing up human doctors to see more patients. Of course, all of this depends on solving the challenges mentioned here. Once society understands the impact agents can have, there will be a demand for evidence that it can be trusted. By establishing where the boundaries lie as we build, test and use it today, we can lay the groundwork for a safe, agentic tomorrow.
Yahoo
18-06-2025
- Business
- Yahoo
5 Revealing Analyst Questions From Elevance Health's Q1 Earnings Call
Elevance Health's first quarter was characterized by notable revenue growth and a positive market reaction, driven by strong momentum across its Carelon services platform and ongoing investments in patient advocacy and digital integration. Management cited robust traction for Carelon's external payer solutions and highlighted the expansion of digital initiatives like HealthOS, which now serves over 88,000 care providers. CEO Gail Boudreaux noted, 'Our patient advocacy solutions supported over 6 million a 95% satisfaction rate, it's become a valuable differentiator.' The quarter also saw progress in integrating recent acquisitions to strengthen home-based and pharmacy services, though higher Medicaid costs and elevated utilization slightly tempered operating margins. Is now the time to buy ELV? Find out in our full research report (it's free). Revenue: $48.89 billion vs analyst estimates of $46.43 billion (14.8% year-on-year growth, 5.3% beat) Adjusted EPS: $11.97 vs analyst estimates of $11.48 (4.3% beat) Adjusted EBITDA: $4.06 billion vs analyst estimates of $3.8 billion (8.3% margin, 7% beat) Management reiterated its full-year Adjusted EPS guidance of $34.50 at the midpoint Operating Margin: 6.4%, down from 8.2% in the same quarter last year Customers: 45.83 million, up from 45.73 million in the previous quarter Market Capitalization: $85.07 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. A.J. Rice (UBS) asked about persistent cost trends in Medicare Advantage and the impact of the Inflation Reduction Act. CFO Mark Kaye explained that elevated costs were anticipated and manageable, with close monitoring of claims data and no material deviations from expectations. Lance Wilkes (Bernstein) focused on Carelon's external growth and specialty pharmacy integration. President Pete Haytaian highlighted strong internal and external demand, especially in risk-based services, and described ongoing integration of specialty pharmacy assets as deliberate and patient-centric. Stephen Baxter (Wells Fargo) inquired about lower-than-expected ACA effectuation rates and their implications for profitability. Kaye responded that lighter effectuation was due to passive Medicaid transitions and projected a single-digit percent attrition in Q2, which has been factored into guidance. Andrew Mok (Barclays) sought clarification on the benefit-expense ratio (MLR) outperformance. Kaye attributed this to a larger-than-expected Medicaid premium tax, which favorably impacted the ratio without affecting overall earnings. Lisa Gill (JPMorgan) questioned the impact of Medicare Part D changes and risk coding for new members. Kaye detailed the seasonality effects caused by the new $2,000 out-of-pocket cap and explained how these changes front-load earnings but do not alter full-year margin expectations. Looking ahead, the StockStory team will be watching (1) the ability of Carelon to sustain external payer growth and successfully integrate recent acquisitions, (2) the outcomes of ongoing Medicaid rate negotiations and their effect on segment margins, and (3) the impact of Medicare Advantage risk adjustment changes and value-based care expansion on overall profitability. Execution in digital health platforms and pharmacy services will also be closely monitored. Elevance Health currently trades at $376.53, down from $407.03 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
